Cargando…

Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222

We report the safety and immunogenicity results in participants administrated with a booster dose of protein subunit vaccine MVC-COV1901 at 12 (Group A) or 24 (Group B) weeks after two doses of AZD1222 (ChAdOx1 nCoV-19). The administration of the MVC-COV1901 vaccine as a booster dose in both groups...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Shu-Hsing, Lin, Yi-Chun, Chen, Cheng-Pin, Cheng, Chien-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609613/ https://www.ncbi.nlm.nih.gov/pubmed/36298566 http://dx.doi.org/10.3390/vaccines10101701

Ejemplares similares

Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial
por: Estephan, Lila, et al.
Publicado: (2023)

A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV
por: Cheng, Shu-Hsing, et al.
Publicado: (2022)

Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial
por: Waits, Alexander, et al.
Publicado: (2022)

A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19
por: Chen, Chih-Jung, et al.
Publicado: (2022)

Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study
por: Huang, Szu-Ting, et al.
Publicado: (2023)

Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial
por: Liu, Luke Tzu-Chi, et al.
Publicado: (2022)

Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data
por: Wanlapakorn, Nasamon, et al.
Publicado: (2022)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
por: Cohen, Guy, et al.
Publicado: (2022)

Safety and Immunogenicity of Homologous and Heterologous Adenoviral-Vectored and mRNA COVID-19 Vaccine Regimens in Radiotherapy Patients
por: Prayongrat, Anussara, et al.
Publicado: (2023)

Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study
por: Hsieh, Szu-Min, et al.
Publicado: (2022)

STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines
por: Padron-Regalado, Eriko, et al.
Publicado: (2022)

AZD-1222: Vaccine-induced thrombotic thrombocytopenia: case report
Publicado: (2022)

AZD 1222: Vaccine induced thrombotic thrombocytopenia: case report
Publicado: (2021)

AZD-1222: Vaccine-induced myocarditis and arrhythmias: case report
Publicado: (2021)

Aseptic meningitis following AZD1222 COVID-19 vaccination
por: Zavari, Arefeh, et al.
Publicado: (2022)

AZD-1222: Vaccine-induced thrombosis and thrombocytopenia: case report
Publicado: (2021)

AZD-1222: Vaccine associated thrombosis and thrombocytopenia: case report
Publicado: (2022)

Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination
por: Assawakosri, Suvichada, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2023)

Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine
por: Lin, Yi-Jiun, et al.
Publicado: (2022)

Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines
por: Coughlan, Lynda
Publicado: (2020)

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection
por: Suah, Jing Lian, et al.
Publicado: (2022)

AZD 1222: Vaccine induced thrombotic thrombocytopenia: 2 case reports
Publicado: (2021)

AZD-1222: Vaccine-induced immune thrombotic thrombocytopenia: case report
Publicado: (2021)

Azd-1222: Vaccine-induced thrombocytopenia and thrombosis: 2 case reports
Publicado: (2022)

AZD-1222: Vaccine-induced immune thrombotic thrombocytopenia: case report
Publicado: (2022)

AZD-1222: Vaccine-induced thrombotic thrombocytopenia: 2 case reports
Publicado: (2022)

Azd-1222: Vaccine-induced immune thrombotic thrombocytopenia: case report
Publicado: (2022)

AZD-1222: Vaccine-induced immune thrombotic thrombocytopenia: case report
Publicado: (2022)

AZD-1222/methotrexate: Post-vaccination myositis and pneumonitis: case report
Publicado: (2022)

Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study
por: Wanlapakorn, Nasamon, et al.
Publicado: (2022)

Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac
por: Nantanee, Rapisa, et al.
Publicado: (2022)

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review
por: Lv, Jingjing, et al.
Publicado: (2022)

Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222
por: Perkmann, Thomas, et al.
Publicado: (2021)

Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital
por: Limpawittayakul, Piyarat, et al.
Publicado: (2022)

AZD1222 (Covishield) vaccination for COVID-19: Experiences, challenges, and solutions in Nepal
por: Sah, Ranjit, et al.
Publicado: (2021)

Aspirin/AZD-1222: Vaccine-induced prothrombotic immune thrombocytopenia: case report
Publicado: (2021)

Acute Eosinophilic Pneumonia Associated With the Anti-COVID-19 Vaccine AZD1222
por: Miqdadi, Amal, et al.
Publicado: (2021)

AZD-1222: Vaccine-induced immune thrombotic thrombocytopenia: 2 case reports
Publicado: (2022)

AZD-1222: Vaccine-induced immune thrombotic thrombocytopenia: 7 case reports
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7fs7p6hdhi5lksnrll2s0hc5kt